The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

LA, Honigberg; AM, Smith; M, Sirisawad; E, Verner; D, Loury; B, Chang; S, Li; Z, Pan; DH, Thamm; RA, Miller; JJ, Buggy

doi:10.1073/pnas.1004594107

Public

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Shared by NobleBlocks on Jul 6, 2010 • 12:00 AM UTC

Authors:

Honigberg LA

Smith AM

Sirisawad M

Abstract

Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases. The Bruton tyrosine kinase (Btk) is specifically required for BCR signaling as demonstrated by human and mouse mutations that disrupt Btk fu...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!